VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx (VNRX) highlighted further details of the DETECSEPS sepsis early‑detection program in France, in which it is an industry partner supplying its Nu.Q® NETs H3.1 blood biomarker. The government‑funded consortium has been awarded €6.3 million (~7.3 million) and will evaluate the approach in 1,000 patients presenting to emergency departments with suspected infection.
DETECSEPS combines the NEWS2 clinical score, Volition’s Nu.Q® NETs H3.1 assay to quantify NETosis, and IDS France’s i10 automated device to generate rapid results and help distinguish patients needing hospital care from those who can be safely sent home. The clinical trials are sponsored and coordinated by AP‑HP with Hospices Civils de Lyon, IHU Sepsis and IDS France as partners. Volition is providing the Nu.Q® H3.1 assay pro bono to enable this evaluation.
VolitionRx (VNRX) has joined the French government-funded €6.3 million (~$7.3 million) DETECSEPS consortium, where its Nu.Q® NETs H3.1 assay has been selected as the sole biomarker for real-world early detection of sepsis in France.
DETECSEPS, led by IHU SEPSIS and coordinated by AP-HP with HCL and industrial partner IDS France, will combine a routinely used clinical score with Volition’s biomarker to quantify sepsis risk on emergency department arrival and guide care within the first 24 hours. IDS France will supply the IDS i10® automated analyzer, which can deliver H3.1 results within about one hour. Sepsis is estimated to cause 21 million deaths globally and around 57,000 deaths annually in France. Volition estimates that, with approximately 166 million sepsis cases per year, the associated testing opportunity represents a multi-billion dollar total addressable market.
VolitionRx (VNRX) has fully prepaid in cash a senior secured convertible promissory note with an original principal of $7.5 million issued to Lind Global Asset Management XII LLC.
The note, dated May 20, 2025 and originally maturing May 20, 2027, is now fully satisfied and all related obligations are discharged. Volition states that this early repayment, more than eight months before the scheduled maturity, removes potential equity dilution linked to the note. A separate senior secured convertible promissory note dated January 7, 2026, with an original principal of $2.4 million, remains outstanding in the amount of $2,041,667.
VolitionRx (VNRX) presented early-stage solid cancer detection data using its Capture-Seq™ technology at the ESMO MAP conference.
In an initial cohort, the assay detected 49/49 cancers, including 23 early stage I/II cases, with no false positives among 21 healthy controls. A second blinded cohort showed detection of 13/14 later-stage cancers with 10 additional healthy controls. In a separate blinded validation cohort of 81 subjects, early-stage detection reached 95% for stage I and II colorectal and lung cancers. Volition targets a $36 billion total addressable market in early cancer detection and Minimal Residual Disease and has filed new patents to protect the Capture-Seq™ platform.
VolitionRx (NYSE American: VNRX) reported first-half 2026 revenue of $1.4 million, a 112% year-over-year increase, and highlighted progress across sepsis, cancer and veterinary pillars targeting an estimated $27+ billion in annualized total addressable markets.
Nu.Q® NETs was validated as an independent predictor of 28‑day mortality and renal replacement therapy in sepsis, ahead of a ~$7.3 million French DETECSEPS program expected to begin recruitment in the third quarter of 2026. Volition advanced a finger‑prick lateral flow Nu.Q® NETs assay correlated with its CE‑marked automated test, and is pursuing NGO and strategic partnerships, particularly in lower‑income countries.
The company plans a conditional lung cancer reimbursement submission in France by the end of 2026 and published peer‑reviewed Capture‑Seq™ data showing over 95% sensitivity for stage I–II cancers with 95% specificity. In companion animals, Volition submitted a Nu.Q® Vet feline lymphoma manuscript (86% sensitivity, 97% specificity) and anticipates a $5 million milestone after publication. Volition also transferred its Nu.Q® NETs assay onto Sysmex Corporation’s platform and is in active licensing discussions with more than a dozen leading diagnostic and liquid biopsy companies.
Volition (NYSE American: VNRX) announced peer-reviewed clinical validation of its Nu.Q® NETs H3.1 biomarker in sepsis, published in Critical Care Medicine alongside an independent editorial. The study reports Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality and need for renal replacement therapy in sepsis and septic shock patients.
The paper shows higher biomarker levels in septic shock than sepsis, and a dose-response relationship with acute kidney injury severity, suggesting potential utility for early risk stratification and intervention. Volition noted that these findings support ongoing licensing discussions in a sepsis-related diagnostics market it estimates at a $2.8 billion total addressable market.
VolitionRx (NYSE AMERICAN: VNRX) reported second quarter 2026 revenue of approximately $0.4 million, roughly in line with Q2 2025, and first-half 2026 revenue of $1.4 million, representing 112% growth over the first half of 2025.
Operating expenses in Q2 2026 were 32% lower year over year, contributing to an operating loss of $4.2 million, down 34% versus Q2 2025. Net cash used in operating activities was $5.2 million, 18% lower than the prior-year quarter. Receipts included $1.2 million from at-the-market equity sales and $4.1 million from a confidentially marketed public offering.
Volition highlighted ongoing licensing discussions with more than a dozen diagnostic and liquid biopsy companies, a collaboration with Sysmex, a Nu.Q Vet feline lymphoma manuscript linked to a potential $5 million milestone, progress toward reimbursement for Nu.Q Lung Cancer, and its first peer-reviewed Capture-Seq liquid biopsy paper. The company estimates its total addressable markets at over $27 billion annually.
Volition (NYSE American: VNRX) reported that its Nu.Q® NETs lateral flow finger-prick prototype showed high correlation with its CE-marked automated Nu.Q® NETs laboratory assay in critically ill sepsis patients, supporting use outside centralized labs in the $3.8 billion global NETosis testing market.
According to Volition, H3.1 nucleosome levels measured from finger-prick samples on a lateral flow device tracked closely with plasma results from the lab assay, with a Spearman correlation of 0.85 and Pearson correlation of 0.881. The study, part of the SUMMIT program, used capillary and plasma samples from Intensive Care patients and indicated feasibility of rapid, point-of-care immune disruption detection, including in sepsis, across settings such as ER, ICU, doctors’ offices, or potentially at home. Volition highlighted 166 million estimated global sepsis cases and 31.5% of global deaths in 2021 linked to sepsis, and said decentralized testing could expand its addressable market, including via NGO and strategic partnerships in low-income countries.
VolitionRx (NYSE American: VNRX) has scheduled its Second Quarter 2026 Earnings and Business Update conference call for Friday, August 14, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time). The call will cover financial and operating results, important Q2 events, subsequent developments, and upcoming milestones.
The call will be hosted by Group Chief Marketing & Communications Officer Louise Batchelor, President and Group CEO Cameron Reynolds, and Group CFO Terig Hughes. Investors can join via regional dial-in numbers using Conference ID 13762190, or access a live audio webcast and replay available until August 28, 2026.
Volition (NYSE AMERICAN: VNRX) announced publication of the first peer‑reviewed paper detailing its new Capture‑Seq™ liquid biopsy technology, which isolates and analyzes >99% pure circulating tumor-derived DNA (ctDNA) from blood plasma by targeting CTCF-bound DNA.
According to Volition, the method combines physical enrichment and bioinformatic filtering to remove virtually all non-tumor cfDNA, generating highly enriched cancer-associated sequence datasets. Early studies reported no false positives and detection of 49/49 cancers in an initial cohort, 13/14 later-stage cancers in a second cohort, and, in a subsequent 81-subject blinded validation, 95% detection of stage I/II colorectal and lung cancers. The company is fast-tracking development, has filed new patents, estimates a total addressable market of approximately $23 billion for multi-cancer early detection and over $13 billion for minimal residual disease, and is in active discussions and technical evaluations with major liquid biopsy and diagnostic companies.